AGWCA
SUPN icon

Annis Gardner Whiting Capital Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$1.03K – 1136
2026
Q1 		$1.03K Hold
20
– – ﹤0.01% 1144
2025
Q4 		$994 Hold
20
– – ﹤0.01% 1054
2025
Q3 		$956 Hold
20
– – ﹤0.01% 992
2025
Q2 		$631 Buy
+20
New +$641 ﹤0.01% 1151

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's SUPN Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 20 shares — an estimated $1.03K sold.

Annis Gardner Whiting Capital Advisors first reported a position in SUPN in Q2 2025 and held it in 4 quarters. The position peaked at $1.03K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 20 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.03K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Supernus Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Annis Gardner Whiting Capital Advisors's Supernus Pharmaceuticals position peaked at $1.03K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.